The global DNA vaccine market was valued at $422.77 million in 2020 and is projected to reach $774.43 million by 2030 registering a CAGR of 6.3% from 2021 to 2030.
DNA vaccines is a small, circular DNA plasmid that encodes one or more protein antigens under the control of a promoter to produce a specific immune response against disease. DNA vaccines are the third-generation vaccines specifically designed to overcome the unsought properties of conventional vaccines. Increase in vulnerability of the population to infectious diseases and rise in number of antibiotics-resistant pathogens have created the need for effective and low-cost vaccination, which would provide long-lasting immunity.
The main driving factors of the DNA vaccines market include, rise in prevalence of cancer and infectious diseases in humans and animals, increase in demand for DNA vaccines owing to its advantages such as low risk of infection, easy transportation and stability at room temperature. In addition, increase in number of antibiotics resistant pathogens has created the need for effective and low-cost vaccination such as DNA vaccines, which would provide long lasting immunity, further boost growth of the DNA vaccines market.
However, lack of immunogenicity associated with DNA vaccines may hamper the growth of the market. Furthermore, limited knowledge of the effects of DNA vaccines on humans is also expected to limit the growth of the market. In contrast, development of novel vaccines using DNA technology, and high growth potential in untapped emerging economies are some factors that are expected to offer lucrative growth opportunities for players in the DNA vaccines market.
The global DNA vaccines market is segmented on the basis of product type, type, end user, and region to provide a detailed assessment of the market. By product type, it is segmented into Oncept, West Nile-Innovator, and Apex-IHN. By type, the market is segmented into therapeutic vaccines and prophylactic vaccines. Based on end user, it is categorized into veterinary clinics, veterinary hospitals. Region wise, the market is analyzed only across North America as DNA vaccine products have not been approved in the other regions.
DNA vaccines is a small, circular DNA plasmid that encodes one or more protein antigens under the control of a promoter to produce a specific immune response against disease. DNA vaccines are the third-generation vaccines specifically designed to overcome the unsought properties of conventional vaccines. Increase in vulnerability of the population to infectious diseases and rise in number of antibiotics-resistant pathogens have created the need for effective and low-cost vaccination, which would provide long-lasting immunity.
The main driving factors of the DNA vaccines market include, rise in prevalence of cancer and infectious diseases in humans and animals, increase in demand for DNA vaccines owing to its advantages such as low risk of infection, easy transportation and stability at room temperature. In addition, increase in number of antibiotics resistant pathogens has created the need for effective and low-cost vaccination such as DNA vaccines, which would provide long lasting immunity, further boost growth of the DNA vaccines market.
However, lack of immunogenicity associated with DNA vaccines may hamper the growth of the market. Furthermore, limited knowledge of the effects of DNA vaccines on humans is also expected to limit the growth of the market. In contrast, development of novel vaccines using DNA technology, and high growth potential in untapped emerging economies are some factors that are expected to offer lucrative growth opportunities for players in the DNA vaccines market.
The global DNA vaccines market is segmented on the basis of product type, type, end user, and region to provide a detailed assessment of the market. By product type, it is segmented into Oncept, West Nile-Innovator, and Apex-IHN. By type, the market is segmented into therapeutic vaccines and prophylactic vaccines. Based on end user, it is categorized into veterinary clinics, veterinary hospitals. Region wise, the market is analyzed only across North America as DNA vaccine products have not been approved in the other regions.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the DNA vaccines market along with the current trends and future estimations to explain the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products of DNA vaccines used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Product Type
- Oncept
- West Nile-Innovator
- Apex-IHN
By Type
- Therapeutic Vaccines
- Prophylactic Vaccines
By End User
- Veterinary Clinics
- Veterinary Hospitals
By Region
- North America
- U.S.
- Canada
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- BOEHRINGER INGELHEIM GmbH (Merial)
- ELI-LILLY (Novartis Animal Health)
- GeneOne Life Science
- GEOVAX LABS, INC
- Inovio Pharmaceuticals (VGX Animal Health)
- Genexine, Inc.
- VIATRIS INC. (Rottapharm Biotech)
- Takara Holdings (Takara Bio)
- ZOETIS INC. (Fort dodge Animal Health)
- Zydus Cadila
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET LANDSCAPE
CHAPTER 4: DNA VACCINE MARKET, BY PRODUCT TYPE
CHAPTER 5: DNA VACCINE MARKET, BY TYPE
CHAPTER 6: DNA VACCINE MARKET, BY END USER
CHAPTER 7: DNA VACCINE MARKET, BY REGION
CHAPTER 8: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- BOEHRINGER INGELHEIM GmbH
- ELI-LILLY (Novartis Animal Health)
- GeneOne Life Science
- GEOVAX LABS INC
- Inovio Pharmaceuticals (VGX Animal Health)
- Genexine Inc.
- VIATRIS INC. (Rottapharm Biotech)
- Takara Holdings (Takara Bio)
- ZOETIS INC. (Fort dodge Animal Health)
- Zydus Cadila
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 123 |
| Published | December 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 422.77 million |
| Forecasted Market Value ( USD | $ 774.43 million |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
